Shalini Chitneni, MD
Hematology & Oncology · Fort Wayne, INNPI 1396951299
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,998 of the $45,717 with a category attached, or 61.2%. Cornerstone Specialty Network LLC accounts for 61.2% of it on its own, with 57 other manufacturers making up the rest. Reporting peaked in 2023 at $15,434 and has fallen 84.8% since, to $2,349 in 2025.
Across 531 payments — averaging $86.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$28K
- Daiichi Sankyo Inc.$4K
- AstraZeneca$2K
- Novartis$1K
- Seagen Inc.$1K
- Incyte Corporation$987
- plus $7K from 52 others
Across 2 payments — averaging $1270.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Consulting fees$8,12418%
- Speaking & faculty fees$27,99861%
- Food & beverage$8,16918%
- Education$5451%
- Other$8812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,717 in reported general payments places this provider in the 85th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 37 | $731,765 |
| ImbruvicaIbrutinib | 26 | $412,495 |
| CabometyxCabozantinib S-Malate | 12 | $289,756 |
| LynparzaOlaparib | 14 | $233,521 |
| KisqaliRibociclib Succinate | 17 | $226,514 |
| BrukinsaZanubrutinib | 12 | $181,123 |
| AlecensaAlectinib Hcl | 16 | $175,100 |
| XtandiEnzalutamide | 12 | $172,174 |
| XareltoRivaroxaban | 35 | $41,450 |
| EliquisApixaban | 61 | $39,659 |
| Abiraterone Acetate | 23 | $24,630 |
| Anastrozole | 149 | $1,678 |
| Ondansetron OdtOndansetron | 45 | $1,038 |
| Letrozole | 64 | $952 |
| Tamoxifen Citrate | 45 | $891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $260 | $731,76537 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $328 | $412,49526 claims |
| Exelixis Inc.Cabometyx | $75 | $289,75612 claims |
| AstraZenecaLynparza | $2,237 | $233,52114 claims |
| NovartisKisqali | $1,484 | $226,51417 claims |
| Beigene USA, Inc.Brukinsa | $29 | $181,12312 claims |
| Genentech USA, Inc.Alecensa | $248 | $175,10016 claims |
| Astellas Pharma US IncXtandi | $43 | $172,17412 claims |
| Johnson & JohnsonXarelto | $590 | $41,45035 claims |
| PfizerEliquis | $313 | $39,65961 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Ahad SadiqFort Wayne$430K
- Zhentao ZhangFort Wayne$167K
- Sreenivasa NattamFort Wayne$120K
- Praveen KolliparaFort Wayne$88K
- Dolly Quispe LeveauFort Wayne$74K
- Matthew CarrFort Wayne$51K
- Ryan GonzalesFort Wayne$38K
- Robert MangesFort Wayne$31K
- Michael TooleFort Wayne$27K
- Melanie ClarkFort Wayne$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.